Clinical Trial

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Dimensions: NCT03155997

Investigators

Affiliations

Organisations

Sponsors/collaborators

Abstract

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Methods

Condition: Breast Cancer

Intervention: Administered orally.

Recruitment information

Gender: All

Trial period

2017-2029

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry